Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
0
Participant gender:
All
Summary
Patients with congestive heart failure will be assessed for safety and clinical effects of
Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.